Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Syros Pharmaceuticals

Next Previous
Drug Profile

Research programme: small molecule therapeutics - Syros Pharmaceuticals

Alternative Names: CDK 11 inhibitors; CDK12 inhibitor; CDK12/12 inhibitors - Syros Pharmaceuticals; Cyclin-dependent kinase 12/13 inhibitors - Syros Pharmaceuticals; SY 351; SY-12882; THZ1; THZ531; WRN inhibitors

Latest Information Update: 21 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syros Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Syros Pharmaceuticals; Whitehead Institute for Biomedical Research
  • Class Antianaemics; Antidementias; Antineoplastics; Small molecules; Urologics
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; Gene expression modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Alzheimer's disease; Autoimmune disorders; Cancer; Ewing's sarcoma; Neuroblastoma; Ovarian cancer; Polycystic kidney disease; Precursor cell lymphoblastic leukaemia-lymphoma; Sickle cell anaemia; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 26 Oct 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top